Avalanche Aims To Ditch IPO Suit Over Eye Drug
Avalanche Biotechnologies Inc. on Wednesday asked a California federal judge to toss a proposed investor class action alleging it knew a gene therapy for vision loss didn't work before its public...To view the full article, register now.
Already a subscriber? Click here to view full article